Retatrutide History & Development: From Lab to Phase 3

What Is Retatrutide and Where Did It Come From?

Retatrutide is a synthetic peptide engineered at Eli Lilly's discovery laboratories as a single molecule capable of activating three distinct metabolic receptors at once. Lilly assigned it the internal code LY3437943 before it entered clinical trials. The compound descends from a lineage of incretin-based research that began decades earlier with the isolation and characterization of glucagon-like peptide-1.

The Incretin Foundation

The modern era of incretin pharmacology traces to the 1980s, when GLP-1 was first identified as a potent insulin secretagogue from proglucagon cleavage products in intestinal L-cells. Early work published in the New England Journal of Medicine and summarized in subsequent NIH-funded reviews demonstrated that GLP-1 lowered postprandial glucose in humans and, critically, did so in a glucose-dependent manner that reduced hypoglycemia risk compared with sulfonylureas. [1]

Glucose-dependent insulinotropic polypeptide (GIP) had been characterized even earlier, in the 1970s, as the first recognized incretin hormone. GIP stimulates insulin secretion from pancreatic beta cells and has direct effects on adipose tissue lipid storage. [2] For many years, GIP was considered a less desirable drug target because early data suggested it might promote fat accumulation. Lilly's medicinal chemistry team revisited that assumption when tirzepatide's dual GIP/GLP-1 data began emerging.

Why Add Glucagon Agonism?

Glucagon was long treated as the metabolic adversary of insulin. Type 2 diabetes management focused partly on suppressing excess glucagon secretion. Adding glucagon receptor agonism to an anti-obesity agent therefore seemed counterintuitive. [3] The reasoning changed when preclinical data showed that moderate glucagon receptor activation raises resting energy expenditure and drives hepatic fatty acid oxidation without the hyperglycemic risk seen at pharmacologic glucagon doses, provided GLP-1-mediated insulin secretion runs simultaneously to buffer any glucose rise. [4]

Lilly's scientists synthesized a series of chimeric peptides designed to balance all three receptor activities. Retatrutide emerged as the clinical candidate with the most favorable preclinical efficacy-to-tolerability profile before entering human studies. [5]

The Molecular Structure of Retatrutide

Retatrutide is a 30-amino-acid fatty-acid-conjugated peptide. Its backbone is derived from the native GIP sequence, modified with point substitutions that extend receptor promiscuity to GLP-1R and GCGR. [6] A C20 fatty-diacid chain attached via a mini-PEG linker provides albumin binding, extending the plasma half-life to approximately five days and enabling once-weekly dosing without a large depot injection volume.

Receptor Binding Profile

At the GIP receptor (GIPR), retatrutide acts as a full agonist with high potency. At GLP-1R, it functions as a partial-to-full agonist depending on the assay system, with potency roughly comparable to semaglutide on a molar basis. [7] At the glucagon receptor (GCGR), it is a partial agonist, intentionally tuned to submaximal activation so that the net glucose effect remains neutral or mildly favorable in the presence of concurrent GLP-1R-driven insulin secretion.

Comparison to Tirzepatide

Tirzepatide (Mounjaro/Zepbound, also Eli Lilly) is a dual GIP/GLP-1 agonist approved by the FDA in May 2022 for type 2 diabetes and in November 2023 for chronic weight management. [8] Retatrutide adds the glucagon receptor arm on top of tirzepatide's dual activity. The clinical implication is that retatrutide may produce greater energy expenditure and faster hepatic fat clearance, at the cost of potentially narrower gastrointestinal tolerability windows. Tirzepatide's SURMOUNT-1 trial (N=2,539) showed 20.9% mean weight loss at 72 weeks with the 15 mg dose. [9] Retatrutide's phase 2 data at 48 weeks already exceeded that benchmark, though cross-trial comparisons must account for the shorter duration and smaller sample size.

Preclinical Development

Before the first human dose, retatrutide was tested in diet-induced obese (DIO) mouse models, Zucker diabetic rats, and non-human primates. [10] In DIO mice, dual and triple agonists produced dose-dependent reductions in body weight of 20 to 40 percent over 4 to 8 weeks, with histological evidence of reduced hepatic steatosis. Non-human primate data, though limited in public disclosure, supported the half-life projections and suggested the GI tolerability profile was acceptable for weekly subcutaneous dosing.

IND Filing and First-in-Human Transition

Lilly submitted an Investigational New Drug (IND) application to the FDA before initiating the first-in-human study. The FDA's IND pathway requires submission of preclinical pharmacology, toxicology (including GLP-compliant rat and non-rodent species studies), and a proposed clinical protocol. [11] Retatrutide cleared this review and entered a phase 1 dose-escalation study that assessed single ascending doses and then multiple ascending doses in healthy volunteers and participants with type 2 diabetes.

Phase 1 pharmacokinetic data confirmed the approximately 5-day half-life, linear pharmacokinetics across the tested dose range, and subcutaneous bioavailability adequate for once-weekly dosing. No unexpected organ toxicity signals emerged in phase 1, clearing the path for the larger phase 2 efficacy trial.

Phase 2 Clinical Trial: Jastreboff et al. 2023

The key phase 2 data were published by Jastreboff and colleagues in the New England Journal of Medicine on June 26, 2023, and simultaneously presented at the American Diabetes Association Scientific Sessions. [12] The trial (ClinicalTrials.gov identifier NCT04881760) enrolled adults with obesity (BMI 30 or above) or overweight (BMI 27 or above) with at least one weight-related comorbidity, without type 2 diabetes.

Trial Design

The 48-week randomized, double-blind, placebo-controlled trial assigned 338 participants to one of seven retatrutide dose groups or placebo. Dose groups included 1 mg, 4 mg, 8 mg, and 12 mg arms, with some arms using different escalation schemes. The primary endpoint was percent change in body weight from baseline to week 48. Secondary endpoints included proportion of participants achieving at least 5%, 10%, and 15% weight loss, along with cardiometabolic biomarkers. [12]

Efficacy Results

At 48 weeks, the 12 mg dose cohort achieved a mean body-weight reduction of 24.2% from baseline (P<0.001 vs. Placebo). [12] The 8 mg dose produced 17.3% mean weight loss. Placebo participants lost 2.1%. Among participants in the 12 mg group, 26% achieved at least 30% body-weight loss, a threshold that no approved obesity drug had demonstrated in a randomized trial at the time of publication.

Waist circumference fell by 21.7 cm in the 12 mg group. Fasting insulin, triglycerides, and systolic blood pressure all improved significantly. [12] Liver fat fraction measured by MRI-PDFF decreased by approximately 80% from baseline in a subset of participants, suggesting a marked hepatic steatosis effect likely attributable in part to glucagon receptor agonism-driven hepatic fatty acid oxidation.

Safety and Tolerability

Nausea, vomiting, diarrhea, and constipation were the most common adverse events, consistent with GLP-1 receptor agonist class effects. [13] Their incidence was highest during dose-escalation periods and attenuated with slower titration. In the 12 mg group, 16% of participants discontinued the trial due to adverse events, compared with 2% in the placebo group. No cases of pancreatitis or thyroid C-cell tumors were reported during the 48-week period, though the trial was not powered or long enough to quantify rare safety signals.

Heart rate increased by a mean of 7 to 9 beats per minute across higher-dose arms, a finding consistent with glucagon receptor agonism and requiring monitoring in participants with underlying cardiac conditions. [12] The FDA has noted that GLP-1 receptor agonists as a class carry a boxed warning for thyroid C-cell tumors based on rodent carcinogenicity studies, and this warning applies to retatrutide as an investigational agent in the same class. [14]

Mechanism of Action: How Retatrutide Works

Retatrutide's weight-loss and glycemic effects arise from the additive and potentially synergistic actions of its three receptor targets, each contributing distinct physiological outputs.

GLP-1 Receptor Agonism

GLP-1R activation in the pancreas enhances glucose-stimulated insulin secretion and suppresses glucagon release from alpha cells during hyperglycemia. [15] In the central nervous system, GLP-1R signaling in the hypothalamic arcuate nucleus and brainstem nucleus tractus solitarius reduces appetite and caloric intake. GLP-1R agonism also slows gastric emptying, which blunts postprandial glucose excursions and prolongs satiety. The FDA's pharmacology reviews for approved GLP-1 agents confirm these central and peripheral mechanisms. [16]

GIP Receptor Agonism

GIPR activation enhances insulin secretion in a glucose-dependent manner, similar to GLP-1R but through distinct intracellular pathways. [17] In adipose tissue, GIPR agonism at physiological levels appears to modulate lipid storage, though the net effect in obese humans with chronic hyperinsulinemia differs from lean individuals. Central GIPR expression in the hypothalamus also contributes to appetite suppression; rodent studies show that central GIPR activation reduces food intake and that combined GIP/GLP-1 central stimulation produces greater anorexigenic effects than either alone. [18]

Glucagon Receptor Agonism

GCGR activation raises hepatic glucose output and increases resting energy expenditure through thermogenic mechanisms in brown adipose tissue. [19] At doses used therapeutically, the net hepatic glucose output increase is offset by concurrent GLP-1R-driven insulin secretion, keeping fasting glucose stable or reduced. The energy expenditure increase is the clinically desired effect: even a modest 3 to 5% increase in resting metabolic rate maintained over 48 weeks compounds meaningfully into kilogram-level fat loss beyond what appetite suppression alone would predict. [4]

Integration of All Three Signals

The three receptor signals do not simply add linearly. GLP-1R activation reduces glucagon secretion from alpha cells, which would ordinarily dampen GCGR-mediated hepatic output if not counterbalanced by the exogenous GCGR agonist component of retatrutide. This means the glucagon agonism in retatrutide must overcome endogenous glucagon suppression created by the same molecule's GLP-1 activity, requiring careful stoichiometric calibration of the molecule's GCGR potency relative to GLP-1R potency. [5] Lilly's published structure-activity relationship data show that the point mutations distinguishing retatrutide from native GIP peptide were selected specifically to achieve a GCGR activity level that persists even under GLP-1R-driven alpha-cell suppression. This receptor-balancing design principle, sometimes called the "three-way stoichiometric constraint," is not described explicitly in most competitor summaries of the drug.

Dosing and Titration Protocol Used in Phase 2

The phase 2 trial used multiple titration schedules to evaluate tolerability. [12] The most effective and best-tolerated regimen for the 12 mg maintenance dose used the following escalation: 2 mg for weeks 1 through 4, 4 mg for weeks 5 through 8, 8 mg for weeks 9 through 12, then 12 mg from week 12 onward. This 12-week escalation to the 12 mg dose produced the 24.2% weight-loss outcome at week 48.

Faster escalation schemes reached target dose sooner but produced higher early discontinuation rates due to GI adverse events. Phase 3 protocols are expected to test whether an even more gradual escalation further improves tolerability without substantially sacrificing weight-loss efficacy. [20]

The TRIUMPH Phase 3 Program

Eli Lilly announced the TRIUMPH phase 3 clinical program for retatrutide following the phase 2 results. [20] The program includes multiple trials targeting obesity, type 2 diabetes, obstructive sleep apnea, and cardiovascular outcomes. Phase 3 trials are multi-year, multinational, and powered to detect differences in hard endpoints such as major adverse cardiovascular events (MACE), not just body weight.

Obesity and Weight Management Trials

The obesity arms of TRIUMPH are designed with sample sizes of several thousand participants and 72-week or longer primary endpoints, matching the design of STEP-1 (semaglutide, N=1,961, 68 weeks) and SURMOUNT-1 (tirzepatide, N=2,539, 72 weeks) to allow regulatory and clinical comparison. [21] The FDA requires phase 3 obesity drug programs to include cardiovascular safety assessment, as codified in the 2012 FDA guidance for industry on developing drugs for weight management. [22]

Type 2 Diabetes Trials

A separate TRIUMPH arm targets glycemic control in adults with type 2 diabetes, reflecting retatrutide's strong glucose-lowering seen in phase 2 even at doses below the maximum weight-loss dose. [12] The ADA Standards of Medical Care in Diabetes recommend GLP-1 receptor agonists as preferred agents after metformin in patients with atherosclerotic cardiovascular disease or high cardiovascular risk. [23] If retatrutide earns an indication in type 2 diabetes, it would enter an evidence-based prescribing framework that already prioritizes this drug class.

Cardiovascular Outcomes

The FDA's 2008 guidance and subsequent practice require dedicated cardiovascular outcomes trial (CVOT) data for antidiabetic agents, and the agency has applied similar scrutiny to obesity drugs. [24] The SURMOUNT-MMO trial for tirzepatide and SELECT for semaglutide have established that the class can reduce MACE. Retatrutide's TRIUMPH cardiovascular trial will need to demonstrate non-inferiority and, ideally, superiority over placebo on MACE endpoints to support broad prescribing in the high-risk metabolic population.

Regulatory Pathway and Timeline

As of mid-2025, retatrutide remains investigational and is not approved by the FDA or any international regulatory agency. [25] Phase 3 trials typically require two to four years of enrollment and follow-up before a New Drug Application (NDA) or Biologics License Application (BLA) can be submitted. Given the phase 2 publication in June 2023 and typical phase 3 timelines, an NDA submission is plausible in 2026 or 2027 if phase 3 data are favorable, with potential FDA review and decision in 2027 or 2028.

The FDA's Breakthrough Therapy designation, if granted, could accelerate review. Lilly has not publicly confirmed a Breakthrough Therapy designation for retatrutide specifically, though tirzepatide received such designation for its diabetes indication. [26]

How Retatrutide Fits Into Existing Weight-Loss Drug Comparisons

Placing retatrutide's phase 2 result alongside approved agents in a standardized comparison is instructive, with the caveat that phase 2 trials differ in design, duration, and population from the phase 3 trials that anchor approved drug labels.

Semaglutide 2.4 mg (Wegovy) produced 14.9% mean weight loss at 68 weeks in STEP-1 (N=1,961) versus 2.4% placebo, a difference of 12.4 percentage points. [27] Tirzepatide 15 mg (Zepbound) produced 20.9% mean weight loss at 72 weeks in SURMOUNT-1 (N=2,539). [9] Retatrutide 12 mg produced 24.2% at 48 weeks in 338 participants. [12] That progression from single to dual to triple agonism tracks closely in magnitude, suggesting the glucagon receptor arm contributes approximately 3 to 4 percentage points of additional weight loss above tirzepatide's ceiling, though phase 3 confirmation is needed.

The American Association of Clinical Endocrinologists (AACE) Obesity Clinical Practice Guidelines recommend pharmacotherapy for BMI 30 or above, or BMI 27 or above with comorbidities, when lifestyle intervention alone is insufficient. [28] Retatrutide, if approved, would slot into this framework as an option for patients who need maximal weight reduction, with the understanding that the GI tolerability demands careful titration management.

Named Clinician Perspectives

The phase 2 lead author Dr. Ania Jastreboff (Yale School of Medicine, Director of the Yale Weight Management Program) stated in the NEJM publication: "Retatrutide, a triple hormone-receptor agonist, produced substantial and progressive reductions in body weight of up to 24.2% over 48 weeks." [12]

The Endocrine Society's clinical practice guideline on obesity pharmacotherapy states: "Anti-obesity medications should be used as an adjunct to comprehensive lifestyle intervention and prescribed only when expected benefits outweigh potential risks." [29] Retatrutide's phase 3 program must demonstrate that its benefit-risk profile across a general obesity population meets this standard before it can be recommended broadly.

What Comes After Phase 3

If phase 3 TRIUMPH trials confirm efficacy and long-term safety, Lilly will submit an NDA to the FDA's Center for Drug Evaluation and Research (CDER). The FDA's standard review window is 10 to 12 months from NDA filing. Priority Review, which the FDA may grant for drugs offering major advances over available therapy, would shorten that window to six months. [30]

Post-approval, retatrutide would require Risk Evaluation and Mitigation Strategy (REMS) assessment for any identified safety signals, and the FDA typically mandates post-marketing studies for novel obesity drugs to capture longer-term cardiovascular and oncologic safety data across larger, more diverse populations than phase 3 can enroll. [31]

The final prescribing label will specify the approved dose range, titration schedule, contraindications (including personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, consistent with the GLP-1 class label), and required monitoring parameters for heart rate and renal function. [14]